Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + eribulin + anlotinib for advanced soft tissue sarcoma
ChiCTR2300071221Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, eribulin and anlotinib in soft tissue sarcoma (STS), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective response rate. Started May 2023; status: recruiting.
02
Drugs
tislelizumaberibulinanlotinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2300071221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071221.